Fig. 8

Predictive value of ECMGPS in therapy. A Waterfall map displaying somatic mutations in the low-risk group. B Waterfall map displaying somatic mutations in the high-risk group. C Kaplan–Meier curves for OS between patients with different risk scores of ECMGPS in the IMvigor cohort. D Violin plot comparing the risk scores of ECMGPS between patients with different immunotherapy responses in the IMvigor cohort. E Violin plot comparing tumor immune dysfunction and exclusion (TIDE) scores between the low- and high-risk groups. F Box plots comparing the sensitivity (IC50) of 10 anti-PCa drugs between the low- and high-risk groups. **P < 0.01, ***P < 0.001. ns not significant